10 results about "CD24" patented technology

Disclosed are a CD24 antibody or an antigen-binding fragment thereof and the medical use thereof. Further, disclosed are a chimeric antibody comprising CDRs of the CD24 antibody, a humanized antibody, a pharmaceutical composition comprising the CD24 antibody or the antigen-binding fragment thereof, and the use thereof as an anticancer drug.

The application discloses humanized anti-CD24 antibodies and application thereof, relates to the technical field of biological medicine, and specifically provides humanized antibodies capable of specifically recognizing CD24 and application thereof. FR regions and constant regions of a mouse-derived anti-CD24 monoclonal antibody are replaced by human-derived FR regions and constant regions, and CDR of the variable region of the mouse-derived anti-CD24 monoclonal antibody is retained, so that a series of anti-CD24 humanized monoclonal antibodies are obtained. The humanized antibodies obtained by the application have an affinity to CD24 antigens which is basically equivalent to that of a human-mouse chimeric anti-CD24 monoclonal antibody WT, and exhibit strong anti-tumor capacity in vivo.

This invention relates to the application of targeting the ABHD17C-BCL6B-CD24 signaling axis in the preparation of pancreatic cancer treatment products, the products comprising diagnostic reagents and targeted drugs. The diagnostic reagent kit contains at least one of the following: a reagent for detecting ABHD17C, a reagent for detecting BCL6B expression, and a reagent for detecting CD24 expression. The targeted drug for improving the efficacy and prognosis of pancreatic cancer treatment contains at least one of the following: a reagent for inhibiting ABHD17C expression, a reagent for inhibiting BCL6B expression, and a reagent for inhibiting CD24 expression. This invention reveals the mechanism by which the ABHD17C-BCL6B-CD24 signaling axis regulates pancreatic cancer, providing a theoretical basis for the precise diagnosis and targeted therapy of pancreatic cancer, and has broad clinical application prospects.

Provided herein are antibody-drug conjugates containing an anti-CD24 antibody conjugated to a cytotoxic agent via a linker, in which the antibody selectively binds to human CD24 protein expressed on cancer cells but not human CD24 expressed in non-cancerous cells; and uses thereof for treating cancer.

The application discloses a VirusTAC platform for tumor cell membrane protein PD-L1 or CD24 targeted degradation and application thereof, and belongs to the technical field of biological medicine. The platform comprises a heterodimer with R1-R2-R3 structure formed by a first polypeptide chain and a second polypeptide chain, wherein R1 is MeV H or a variant thereof; R2 is a linker composed of R4 and R5, R4 is an IgG Fc region; R5 is a linker that can be cut by a protease; and R3 is a target protein binding domain PD-L1 antibody or CD24 antibody. The platform can specifically recognize tumor high-expression receptors and induce rapid endocytosis of cells by means of tumor-specific expression and efficient endocytosis characteristics of Nectin-4, so as to overcome the defects of the existing TPD technology and realize effective regulation of various target proteins.

The present invention relates to a novel method for the diagnosis, prognosis, stratification and / or therapy monitoring of cancer diseases in patients. The method is based on the determination of CD3+ tumor infiltrating lymphocyte levels and CD24 expression. The novel biomarker combination of the present invention allows the diagnosis, prognosis, stratification and / or therapy monitoring of various cancer diseases. Furthermore, diagnostic kits for performing the non-invasive method of the present invention are provided.

This invention discloses a shuttle peptide targeting YY1S247 phosphorylation and its application. The sequence of the shuttle peptide is shown in SEQ ID NO: 1. RQIKIWFQNRRMKWKK is a part of the Drosophila melanogaster tentacles peptide, used to provide cell penetration; PKKKRKV is the nuclear localization sequence of the SV40 large T antigen, used to guide the peptide into the cell nucleus; QIIGENSPPDYSE is the surrounding sequence of the YY1S247 site. The results show that the shuttle peptide (CPP) of this invention can competitively and specifically inhibit phosphorylation at the YY1S247 site, thereby inhibiting CD24 expression and enhancing the therapeutic effect of EGFR-TKIs.

Provided are a group CD24 binding proteins and uses thereof. Specifically provided is a group of antigen binding proteins, wherein cells expressing the antigen binding protein can have cytotoxicity and safety. Also provided is a use of the antigen binding protein in the preparation of a medication.

Provided herein are CD24 binding antibodies, and methods of making and using the same. These antibodies may be useful for the treatment of a disease or condition such as cancer.

The present invention pertains to anti-CD24 antibodies which bind CD24 in an O-glycosylation-dependent manner. Thereby, the antibodies are specific for tumor-associated CD24. The invention further provides pharmaceutical compositions containing said anti-CD24 antibodies and their use in cancer treatment.